This document is a publication of a United States Patent and Trademark Office (USPTO) patent application, specifically application number US20260083750A1, filed on August 24, 2023, and published on March 26, 2026. The application, titled "Small molecule inhibitors of KRAS proteins for cancer treatment," discloses compounds of Formula (I) or their pharmaceutically acceptable salts, which are designed to inhibit specific mutant forms of the Kirsten rat sarcoma (KRAS) protein (G12C, G12D, G12V, and/or G13D). These compounds are presented as having potential therapeutic utility for treating cancer, and the disclosure includes pharmaceutical compositions and methods for their use in cancer therapy and prophylaxis.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future developments in cancer therapeutics. Pharmaceutical companies and drug manufacturers involved in oncology research and development should be aware of this disclosure as it may relate to their intellectual property landscape and future drug development strategies. No immediate actions are required from a compliance perspective, but monitoring patent filings in this therapeutic area is advisable for strategic planning.